🎙️ What does the future hold for people living with NMOSD and MOGAD? With new treatments emerging and research advancing, there are important reasons for hope.

As part of Patient Community Day 2026, we're pleased to share the second episode in our two-part ECTRIMS Podcast series, exploring the latest research and the perspectives of people living with MS and related neurological conditions.

Host Brett Drummond sits down with Taylor Ann Macey, Director of Patient Engagement at the Sumaira Foundation who lives with NMOSD, and Dr Eoin Flanagan, Professor of Neurology at Mayo Clinic, for a conversation about scientific progress and lived experience.

What are the challenges of living with a rare neuroimmune condition?
How are new treatments changing the outlook for NMOSD and MOGAD?
And why are the involvement of people with lived experienceand so important in shaping future research?

From the isolation that can come with a rare diagnosis to the growing optimism around treatment and research, this conversation highlights both the challenges and the possibilities ahead.

This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

🎙️ What does the future hold for people living with NMOSD and MOGAD? With new treatments emerging and research advancing, there are important reasons for hope.

What are the challenges of living with a rare neuroimmune condition?
How are new treatments changing the outlook for NMOSD and MOGAD?
And why are the involvement of people with lived experienceand so important in shaping future research?

From the isolation that can come with a rare diagnosis to the growing optimism around treatment and research, this conversation highlights both the challenges and the possibilities ahead.

NMOSD & MOGAD: New Treatments and Hope f...